Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 19/20 | 0.68 |
| ▸ | HCRTR2 | O43614 | 19/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977862 | 0.89 | HCRTR1 (0.71) | HCRTR1HCRTR2 | |
| SCHEMBL9977854 | 0.85 | HCRTR1 (0.77) | HCRTR1HCRTR2 | |
| SCHEMBL15327031 | 0.85 | HCRTR1 (0.71) | HCRTR1HCRTR2 | |
| SCHEMBL9977748 | 0.84 | HCRTR1 (0.81) | HCRTR1HCRTR2 | |
| SCHEMBL9977815 | 0.81 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL9977882 | 0.81 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL15326967 | 0.78 | HCRTR1 (0.53) | HCRTR1HCRTR2TRPV1 | |
| SCHEMBL9977759 | 0.77 | HCRTR1 (0.49) | HCRTR1HCRTR2TRPV1 | |
| SCHEMBL9977897 | 0.76 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL9977808 | 0.75 | HCRTR1 (0.89) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | claimed |
| EP-2653469-A1 | PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-10-23 | — | — | EP | claimed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2653469-A1 | PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012081692-A1 | PYRAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | HCRTR1, HCRTR2, NPY4R | HCRTR1 1/4885HCRTR2 2/4885TRPV1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.